Middle East and Africa Point-of-Care Molecular Diagnostics Market

Market Introduction

Point-of-care molecular diagnostics include portable devices, and assays & kits used to detect and diagnose diseases in human samples, such as throat swab, blood, serum, and stool. Molecular diagnostics are shifting from centralized laboratories to decentralized point-of-care molecular testing. Due to its simplicity, convenience, rapid turnaround time, and potential to improve patient outcomes, POCT is rapidly gaining traction.

Moreover, the growing demand for specific viral detection methods that consume less time for timely infection control is expected to bolster the market growth during the forecast period.

South Africa has reported the highest COVID-19 cases in the Middle East and Africa, followed by Saudi Arabia and the UAE, among others. The Saudi government policies have been favoring the proliferation of domestic pharmaceutical manufacturers; the government has lifted import duties on raw materials and intermediate products and made financing easy by supporting interest-free funding. Similarly, the continuously increasing incidence of COVID-19 is creating a huge demand for kits and reagent used in its diagnosis. In April 2020, BGI Group, a Chinese genomics company, and Group-42, a UAE technology company, unveiled a new massive-throughput laboratory in the UAE to support testing and diagnosis of the novel coronavirus. According to the BGI Group, the lab will use RT-PCR diagnostic kits that have been approved by medical regulatory authorities in China, Europe, the US, and Japan. As point-of-care molecular diagnostics kits are majorly used in the detection of SARS-CoV-2, the pandemic is fueling the market growth.

Market Overview and Dynamics

The Middle East & Africa Point-of-Care Molecular Diagnostics market is expected to reach US$ 212.9 million by 2028 from US$ 94.0 million in 2021. The market is estimated to grow at a CAGR of 12.4% from 2021–2028. Point-of-care (POC) molecular tests are accurate and scalable that increase the scope for the diagnosis of diseases, which can be done in the community and outside the laboratory setting. Compared with laboratory testing, point-of-care molecular diagnostics provides various advantages such as fewer clinic visits, shorter hospital stays, better drug therapy optimization, and less inappropriate drug use. The healthcare sector is undergoing huge transformation due to the emergence of new and effective technologies across the sector. Thus, the growing demand for effective diagnostics that consumes less time than laboratory testing drives the demand for POC molecular assays and kits propelling the growth of Middle East & Africa point-of-care molecular diagnostics market over the forecast period.

Key Market Segments

In terms of product & services, the assays and kits segment accounted for the largest share of the Middle East & Africa Point-of-Care Molecular Diagnostics market in 2020. In terms of technology, the PCR segment accounted for the largest share of the Middle East & Africa Point-of-Care Molecular Diagnostics market in 2020. In terms of application, the infectious diseases segment accounted for the largest share of the Middle East & Africa Point-of-Care Molecular Diagnostics market in 2020. In terms of end user, the diagnostic laboratories segment accounted for the largest share of the Middle East & Africa Point-of-Care Molecular Diagnostics market in 2020.

Major Sources and Companies Listed

A few major primary and secondary sources referred to for preparing this report on the Point-of-Care Molecular Diagnostics market in Middle East & Africa are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are bioMérieux SA, F. Hoffmann-La Roche Ltd., Danaher Corporation, Enzo Biochem, Inc., Abbott, Meridian BioScience, Inc., Biocartis, Quidel Corporation, and Bio-Rad Laboratories, Inc.

Reasons to Buy Report

• To understand the Middle East & Africa Point-of-Care Molecular Diagnostics market landscape and identify market segments that are likely to guarantee a strong return
• To comprehend the ever-changing market landscape and stay ahead in competition
• To efficiently plan merger and acquisition, and partnership deals in the Middle East & Africa Point-of-Care Molecular Diagnostics market by identifying segments with the most promising probable sales
• To make knowledgeable business decisions from perceptive and comprehensive analysis of the market performance of various segments
• To obtain market revenue forecast of the Middle East & Africa Point-of-Care Molecular Diagnostics market based on various segments for the period 2021–2028

MIDDLE EAST & AFRICA POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SEGMENTATION

By Product & Services

• Assays and Kits
• Instruments
• Services and Software

By Technology

• PCR
• Isothermal Nucleic Acid Amplification Technology (INAAT)
• Other Technologies

By Application

• Infectious Diseases
• Oncology
• Hematology
• Prenatal Testing
• Endocrinology
• Other Applications

By End User

• Hospitals and Clinics
• Diagnostic Laboratories
• Research and Academic Institutes
• Others

By Country

• Middle East & Africa

• • • • UAE
      • Saudi Arabia
      • South Africa
      • Rest of Middle East & Africa

Companies Mentioned

1. bioMérieux SA
2. F. Hoffmann-La Roche Ltd.
3. Danaher Corporation
4. Enzo Biochem, Inc.
5. Abbott
6. Meridian BioScience, Inc.
7. Biocartis
8. Quidel Corporation
9. Bio-Rad Laboratories, Inc.

Middle East and Africa Point-of-Care Molecular Diagnostics Strategic Insights

Strategic insights for the Middle East and Africa Point-of-Care Molecular Diagnostics provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Middle East and Africa Point-of-Care Molecular Diagnostics Report Scope

Middle East and Africa Point-of-Care Molecular Diagnostics Regional Insights

The geographic scope of the Middle East and Africa Point-of-Care Molecular Diagnostics refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.